Avalo Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2011-01-01

Employees: 19

Market Cap: -

Website: http://www.avalotx.com

Introduction: Avalo Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of treatments for rare and orphan diseases. Its lead product candidates include CERC-801, CERC-802, and CERC-803, which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Rockville, MD.

Clinical Trials

A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa

Phase 2

Recruiting

Conditions: Hidradenitis Suppurativa

Interventions: Drug: AVTX-009 Regimen 1
Drug: AVTX-009 Regimen 2
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-29

Lead Sponsor: Avalo Therapeutics, Inc.

Target Recruit Count: 180

Registration Number: NCT06603077

Locations: 🇦🇺
Clinical Site 1202, Carlton, Victoria, Australia
🇺🇸
Clinical Site 1022, Scottsdale, Arizona, United States
🇺🇸
Clinical Site 1026, Tucson, Arizona, United States

and more 52 locations

A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Phase 2

Completed

Conditions: Non-Eosinophilic Asthma

Interventions: Drug: Placebo
Drug: AVTX-002

First Posted Date: 2022-03-21

Last Posted Date: 2023-07-21

Lead Sponsor: Avalo Therapeutics, Inc.

Target Recruit Count: 91

Registration Number: NCT05288504

Locations: 🇺🇸
Meridian Clinical Research, Portsmouth, Virginia, United States
🇺🇸
Family Allergy and Asthma Research Institute, Louisville, Kentucky, United States
🇺🇸
Midwest Clinical Research, Saint Louis, Missouri, United States

and more 20 locations

A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations

Phase 1

Withdrawn

Conditions: Lymphatic Malformation

Interventions: Drug: CERC-006

First Posted Date: 2021-08-06

Last Posted Date: 2022-03-22

Lead Sponsor: Avalo Therapeutics, Inc.

Registration Number: NCT04994002

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: AEVI-007

First Posted Date: 2020-12-17

Last Posted Date: 2024-02-29

Lead Sponsor: Avalo Therapeutics, Inc.

Target Recruit Count: 13

Registration Number: NCT04671251

Locations: 🇺🇸
James R. Berenson, MD., Inc., West Hollywood, California, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States

and more 3 locations

Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis

Phase 1

Terminated

Conditions: Crohn Disease
Ulcerative Colitis

Interventions: Drug: MDGN-002

First Posted Date: 2017-05-30

Last Posted Date: 2024-02-26

Lead Sponsor: Avalo Therapeutics, Inc.

Target Recruit Count: 8

Registration Number: NCT03169894

Locations: 🇺🇸
Advanced Research Institute, Inc., New Port Richey, Florida, United States
🇺🇸
Sweet Hope Research Specialty, Inc., Hialeah, Florida, United States
🇺🇸
Egleston Hospital, Atlanta, Georgia, United States

and more 10 locations

A Study of Intermittent Doses of CERC-301 in MDD

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Placebo
Drug: CERC-301

First Posted Date: 2015-06-02

Last Posted Date: 2017-09-28

Lead Sponsor: Avalo Therapeutics, Inc.

Target Recruit Count: 115

Registration Number: NCT02459236

Locations: 🇺🇸
Richmond Behavioral Associates, Staten Island, New York, United States
🇺🇸
Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States
🇺🇸
Pharmacology Research Institute (PRI), Newport Beach, California, United States

and more 10 locations

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

Phase 2

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: CERC-301
Other: Placebo

First Posted Date: 2013-09-13

Last Posted Date: 2017-12-21

Lead Sponsor: Avalo Therapeutics, Inc.

Target Recruit Count: 1357

Registration Number: NCT01941043

Locations: 🇺🇸
Behavioral Research Specialists, Glendale, California, United States
🇺🇸
ProScience Research Group, Culver City, California, United States
🇺🇸
Bioscience Research, Mount Kisco, New York, United States

and more 20 locations

An Exploratory Study of FP01 Lozenges in Subjects With Chronic Refractory Cough

Phase 2

Completed

Conditions: Chronic Refractory Cough

Interventions: Drug: FP01
Drug: placebo

First Posted Date: 2012-10-11

Last Posted Date: 2014-11-05

Lead Sponsor: Avalo Therapeutics, Inc.

Target Recruit Count: 83

Registration Number: NCT01703923

Locations: 🇺🇸
Allergy & Asthma Associates of Santa Clara Valley, San Jose, California, United States
🇺🇸
Sher Allergy Specialists, Largo, Florida, United States
🇺🇸
American Health Research, Charlotte, North Carolina, United States

and more 5 locations